.... More wrong input from a competitors executive which by the way and getting hurt by MDXG.
Having been around MDXG for some time, I can say the Organogenesis graphs are just like the Shire graphs. It's expensive because about 75% is thrown away.
Regarding the DOJ investigations, a company must press release that kind of information.
First off, its grafts, not graphs. Second, this guys' company is not getting hurt by Epifix (yet) and it is not organogenesis either. Third, so far everything he told me is completely accurate. Fourth, you should read my posts more carefully.
Facts are wrong. Any DOJ contact would have been related to people they worked with or for at ABH. Mimedx hired none of the people directly involved in any DOJ investigation as those people are unemployed or work for other companies. MDXG has just scratched the surface and I am glad that you will not be along to enjoy the run with the rest of us.